Clinical trials: Hepatic Function
Hepatic Insufficiency & Healthy Subjects
Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function
This study is designed to evaluate the safety and pharmacokinetics of zanubrutinib in subjects with impaired liver function in comparison with healthy subjects
- Trial name
- NCT03465059
- Testing
- Zanubrutinib
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- BeiGene
Liver Cirrhosis, Liver Cancer
Development of a Set of Auxiliary Decision-making System for the Perioperative Period of Hepatectomy Based on Static CT and Artificial Intelligence.
The study will prospectively recruit patients with chronic liver disease and liver cancer for static CT scans to establish a high-definition CT database.
- Trial name
- NCT07056270
- Testing
- static CT scans
- Volunteers
- 500 people
- Sponsor
- Tongji Hospital
Hepatic Impairment, Healthy
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose
The main aim of this study is to understand how moderate and severe liver impairment (based on the Child-Pugh classification) affects the body's processing of a single dose of 10 mg maximum of palovarotene, compared to healthy…
- Trial name
- NCT06908954
- Testing
- Palovarotene
- Where
- 4 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Ipsen
Diabetic Kidney Disease
Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function
The primary objective of this study is to evaluate the pharmacokinetics (PK) of selonsertib in participants with impaired hepatic function relative to matched, healthy controls.
- Trial name
- NCT02509624
- Testing
- Selonsertib
- Where
- 5 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
NAFLD (Nonalcoholic Fatty Liver Disease), Hep A
Comparative Effects of Mediterranean and DASH Diet on Hepatic Function
Participants were assigned into three groups Control group recieving general dietary guidelines, Mediterranean diet intervention group DASH dietary intervention group
- Trial name
- NCT07622680
- Testing
- Dietary guidelines for fatty liver, Mediterranean diet, DASH diet
- Where
- Pakistan
- Volunteers
- 75 people
- Sponsor
- University of Lahore
Non-Alcoholic Fatty Liver Disease (NAFLD)
Proliverenol Supplementation for Non-Alcoholic Fatty Liver Disease (NAFLD)
This is a 4-arm, prospective, randomized, double-blind, double-dummy, and placebo-controlled clinical study comparing Proliverenol at a dose of 500 mg twice daily; Proliverenol at a dose of 1000 mg once daily; Proliverenol at a…
- Trial name
- NCT06127225
- Testing
- Proliverenol
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Dexa Medica Group
Hepatic Impairment, Healthy Participants
Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function
The primary objective of this study is to assess the pharmacokinetics (PK) of linzagolix in subjects with varying degrees of impaired hepatic function compared to match control subjects with normal hepatic function
- Trial name
- NCT03962049
- Testing
- Linzagolix
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ObsEva SA
Normal Hepatic Function, Impaired Hepatic Function
Effect of Hepatic Impairment on LDE225..
This study is to evaluate the pharmacokinetics and safety of 800 mg of LDE225 in subjects with impaired hepatic function and healthy subjects with normal hepatic function.
- Trial name
- NCT01764776
- Testing
- LDE225
- Where
- 5 sites in United States, Belgium and 3 more
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Severe Pediatric Obesity (BMI > 97° pc -According to Centers for Disease Control and Prevention BMI Charts-), Altered Liver Function Tests
Obalon in Children With Severe Obesity
The ongoing global rise in the prevalence of overweight and obesity among all ages and among all ethnic groups, figures into a real epidemic phenomenon.
- Conditions
- Severe Pediatric Obesity (BMI > 97° pc -According to Centers for Disease Control and Prevention BMI Charts-), Altered Liver Function Tests, Glycemic Intolerance
- Trial name
- Obalon (NCT02137330)
- Testing
- Swallowable Obalon® Gastric Balloon
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Protective Effect in TB-DIH, TB-DIH Means: Drug Induced Liver Function Abnormalities
The Protective Effect for Liver Organ in Patients With Anti-TB Drugs Using of Acetylcysteine (NAC)
Animal studies have shown that INH-RIF-induced oxidative injury can be prevented by supporting the cellular antioxidant defense mechanism by N-acetylcysteine (NAC).
- Trial name
- NCT02889757
- Testing
- Acteylcysteine
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- Far Eastern Memorial Hospital
Analgesic Allergy
Pharmacokinetic Study of Intranasal RX0041-002 in Hepatic-Impaired Individuals and Subjects With Normal Hepatic Function
The primary objective of this study is to evaluate the potential effect of hepatic impairment on the systemic pharmacokinetics of RX0041-002 following single dose intranasal administration.
- Trial name
- NCT02775981
- Testing
- RX0041-002
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pharmaceutical Project Solutions, Inc.
Alcohol Related Disorders
Hepatic Function During and Following Three Days of Acetaminophen Dosing in Alcoholics
The study objective was to determine whether liver injury develops in alcoholic patients who ingest therapeutic doses of APAP for three consecutive days.
- Trial name
- NCT00402571
- Testing
- acetaminophen
- Where
- 2 sites in United States
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Denver Health and Hospital Authority
Moderate Hepatic Impairment, Healthy
Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment
This multiple-center, nonrandomized, open label, parallel group, single dose study will be conducted in male and female subjects with normal hepatic function or moderate (Child-Pugh Class B) hepatic impairment to evaluate the…
- Trial name
- NCT04534699
- Testing
- KBP-5074
- Where
- 3 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- KBP Biosciences
Lipid Metabolism Disorders
High Dose Intravenous Fish Oil Reduces Inflammation
Retrospective analysis of 51 patients (27 female, 24 male, mean age 51.5±12.6 years) who received all-in-one PN including amino acids, glucose and lipids supplemented with pure fish oil LE was performed.
- Trial name
- NCT04467138
- Testing
- Omegaven
- Where
- Poland
- Volunteers
- 51 people
- Sponsor
- Stanley Dudrick's Memorial Hospital
Pharmacokinetics, Hepatic Insufficiency
Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)
Evaluate the potential effect of hepatic or renal impairment on the pharmacokinetics, safety and tolerability of BAY 1841788 (ODM-201).
- Conditions
- Pharmacokinetics, Hepatic Insufficiency, Renal Insufficiency
- Trial name
- NCT02894385
- Testing
- BAY1841788
- Where
- 2 sites in Germany
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Bayer
Hepatitis B, Chronic
Optimal Time for Tenofovir Treatment of Anti-Hepatitis B Virus (HBV) During the Pregnancy
To determine the optimal time for the Tenofovir treatment of anti-Hepatitis B Virus (HBV) during the pregnancy among women with chronic HBV infection and high HBV DNA load.
- Trial name
- NCT02510963
- Testing
- Tenofovir Disoproxil Fumarate
- Where
- China
- Volunteers
- 300 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Pharmacokinetics, Hepatic Impairment
MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function
The goal of this clinical trial to learn how MDMA is processed in people with abnormal liver function. The main questions it aims to answer are: Do people with abnormal liver function experience greater absorption of MDMA? Does…
- Trial name
- NCT03606538
- Testing
- Midomafetamine HCl
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Resilient Pharmaceuticals
Beta Thalassemia Major Anemia
The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major
Beta Thalassemia is a major public health problem in Mediterranean countries.In Egypt, it is considered as the most common chronic hemolytic anemia.one of the major complications in this inherited disorder is iron overload which…
- Trial name
- NCT02984475
- Testing
- Metformin
- Where
- 2 sites in Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Hepatic Impairment (HI)
Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic Impairment
This is a single-center, non-randomized, open-label, parallel-group, single-dose study designed to evaluate the safety and pharmacokinetic (PK) profile of vorolanib tablets in participants with hepatic impairment.
- Trial name
- NCT07809802
- Testing
- vorolanib
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non-cystic Fibrosis Bronchiectasis (NCFBE)
Investigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Hepatic Impairment
The study is being conducted to compare the pharmacokinetics, safety of HSK31858 in subjects with mild, moderate, severe hepatic impairment and normal hepatic function.
- Trial name
- NCT07913009
- Testing
- HSK31858 tablets
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.